FindTrial
Sign In

Development of new endpoints and analysis methods for clinical trials in COVID-19 patients

Development of new endpoints and analysis methods for clinical trials in COVID-19 patients - Development of new endpoints and analysis methods for clinical trials in COVID-19 patients

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000051337
Enrollment
1063
Registered
2023-06-14
Start date
2021-06-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Sponsors

National Center for Global Health and Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients enrolled and randomized in the ACTT-1 trial

Exclusion criteria

Exclusion criteria: Patients enrolled and randomized in the ACTT-1 trial

Design outcomes

Primary

MeasureTime frame
Time to death Time to improvement Daily symptoms during the study period (7-category ordinal scale data)—

Countries

Japan

Contacts

Public ContactYUKARI UEMURA

National Center for Global Health and Medicine Center for Clinical Research

yuemura@hosp.ncgm.go.jp0332027181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026